Results 51 to 60 of about 1,327 (120)

PSMA PET‐directed radiotherapy for prostate cancer: From precision planning to future innovations

VIEW, Volume 7, Issue 1, February 2026.
Prostate‐specific membrane antigen (PSMA) positron emission tomography (PET) imaging enables highly sensitive detection of prostate cancer recurrence and precise lesion mapping. This review summarizes current evidence and emerging applications of PSMA PET in radiotherapy, including diagnostic staging, target delineation, adaptive planning, and outcome ...
Wenpeng Huang, Jessica C. Hsu, Ruobing Li, Kexin Lan, Xin Qi, Yuchun Wei, Weibo Cai, Hongzhen Li   +7 more
wiley   +1 more source

Anlotinib added to third generation EGFR tyrosine kinase inhibitor therapy for advanced NSCLC patients with oligo-progression: a retrospective study (ALTER-L058)

Frontiers in Pharmacology
ObjectiveTo investigate the efficacy of anlotinib, an antiangiogenic multikinase inhibitor, as an add-on therapy to first-line epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) for patients with EGFR-mutant non-small cell lung ...
Fei Zhou, Minglei Zhuo, Hongmin Wang, Nong Yang, Jisheng Li, Shi Jin, Zhengxiang Han, Guilin Zeng, Jun Liu, Yang Song, Kangwu Wang, Dabing Huang, Ling Li, Jian Chen, Jinghui Bai, Fengming Ran, Caicun Zhou   +16 more
doaj   +1 more source

Salvage Surgery for Primary Renal Pelvic Urothelial Carcinoma After Enfortumab Vedotin: A Case of Durable Remission With Nectin‐4 Loss

IJU Case Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Introduction Enfortumab vedotin is a standard therapy for advanced urothelial carcinoma, but its efficacy may be limited by acquired resistance and spatial heterogeneity of Nectin‐4 expression. Case Presentation We report the case of a 76‐year‐old woman with cT3N2M0 left renal pelvic urothelial carcinoma that was treated with first‐line ...
Takahito Wakamiya, Yuya Iwahashi, Hiroki Kawabata, Satoshi Muraoka, Shimpei Yamashita, Fumiyoshi Kojima, Yasuo Kohjimoto   +6 more
wiley   +1 more source

Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy

Frontiers in Oncology, 2019
Introduction: Therapy options for patients with oligoprogressive malignant pleural mesothelioma (MPM) are limited. Stereotactic Body Radiotherapy (SBRT) may be a promising therapeutic option, as it delivers a localized ablative dose of radiation and ...
Christina Schröder, Isabelle Opitz, Matthias Guckenberger, Rolf Stahel, Walter Weder, Robert Förster, Nicolaus Andratschke, Olivia Lauk   +7 more
doaj   +1 more source

Clear Cell Renal Cell Carcinoma: Rare and Atypical Metastatic Localizations—A Case Series

Case Reports in Urology, Volume 2026, Issue 1, 2026.
Introduction Clear cell renal cell carcinoma (ccRCC) is the most prevalent subtype of kidney cancer, characterized by its high degree of vascularity and metastatic potential. Although common metastatic sites include the lungs, lymph nodes, bones, liver, adrenal glands, and brain, rare localizations, such as those observed in the pancreas, gallbladder ...
Roosvelt Tessa Djambong, Bril Laurel Follah Feudjio, Stéphane Rysselinck, Emmanuel Seront, Günter Niegisch, Christina Neppl, Alexander Müller, Kalyani Sen   +7 more
wiley   +1 more source

Management of Metastatic Pulmonary Spindle Cell Carcinoma With Upfront Pembrolizumab‐Chemotherapy and Subsequent Ipilimumab–Nivolumab Salvage Therapy: A Case Report

Case Reports in Oncological Medicine, Volume 2026, Issue 1, 2026.
Sarcomatoid carcinoma is a heterogeneous and rare subset of non–small cell lung cancers (NSCLCs), comprising pleomorphic carcinoma, spindle cell carcinoma, giant cell carcinoma, pulmonary blastoma, and carcinosarcoma. Pulmonary spindle cell carcinoma accounts for less than 1% of all NSCLC cases.
Raheel Siddiqui, Suneeba Chattha, Nour Daboul, Jose I. Mayordomo   +3 more
wiley   +1 more source

Artificial Intelligence–Guided Clinical Decision Support for Immunotherapy in Advanced Hepatocellular Carcinoma: From Benefit–Risk Stratification to Adaptive Management

International Journal of Clinical Practice, Volume 2026, Issue 1, 2026.
Immune checkpoint inhibitor–based regimens have become central to the systemic management of advanced hepatocellular carcinoma (HCC). Nevertheless, substantial heterogeneity persists in treatment efficacy, duration of response, toxicity, and preservation of liver function.
Tian Liang, Anchun Mo, Ke Su
wiley   +1 more source

Assessing Second‐Line Treatment Strategies and Outcomes in Epidermal Growth Factor Receptor (EGFR) Oncogene‐Driven Stage IV Non‐Small Cell Lung Cancer, Following a First‐Line EGFR‐TKI Therapy

Cancer Reports, Volume 8, Issue 12, December 2025.
ABSTRACT Background Oncogene‐driven metastatic non‐small cell lung cancer (mNSCLC) is associated with poor survival outcomes, despite advancements in first‐line tyrosine kinase inhibitor (TKI) therapies. Aims This study aimed to characterise second‐line treatment strategies for epidermal growth factor receptor (EGFR)‐driven mNSCLC, and to evaluate ...
Meghana Maddula, Annelise Decaria, Bea Brown, John Simes, Michael Boyer, Venessa Chin   +5 more
wiley   +1 more source

Management of oligometastatic and oligoprogressive epidermal growth factor receptor mutated non-small cell lung cancer patients: state of the art of a combined approach

Exploration of Targeted Anti-tumor Therapy
Recently, the development of targeted therapy approaches such as those based on tyrosine kinase inhibitor (TKI) greatly improved the clinical outcomes of patients affected by oncogene addicted advanced non-small cell lung cancer (NSCLC).
Francesca Di Pressa, Fabiana Perrone, Anna Benini, Frank Lohr, Marcello Tiseo, Alessio Bruni   +5 more
doaj   +1 more source

Metastasis-Directed Stereotactic Body Radiotherapy in Prostate Cancer Patients Treated with Systemic Therapy and Undergoing Oligoprogression: Report on 11 Consecutive Cases

Radiation
Background: Stereotactic body radiotherapy (SBRT) targeted at metastatic sites of disease progression is emerging as a potential therapeutic approach for managing oligoprogressive prostate cancer. However, a definitive benefit has yet to be demonstrated.
Emanuele Chioccola, Mara Caroprese, Christina A. Goodyear, Angela Barillaro, Caterina Oliviero, Stefania Clemente, Chiara Feoli, Luigi Formisano, Antonio Farella, Laura Cella, Manuel Conson, Roberto Pacelli   +11 more
doaj   +1 more source